View ValuationKOREA PHARMA 将来の成長Future 基準チェック /06現在、 KOREA PHARMAの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長23.8%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 29KOREA PHARMA Co., Ltd. announced that it has received KRW 15 billion in fundingOn May 28, 2026, KOREA PHARMA Co., Ltd. closed the transaction.お知らせ • May 22KOREA PHARMA Co., Ltd. announced that it expects to receive KRW 15 billion in fundingKOREA PHARMA Co., Ltd. has announced a private placement of Series 5 Unregistered Unsecured Private Convertible Bonds of the company to raise gross proceeds of KRW 15,000,000,000 on May 20, 2026. The transaction includes participation from The Time-M Private Equity Trust advised by Samsung Securities Co., Ltd for KRW 2,000,000,000, NH Absolute Return General Private Investment Trust No. 1 advised by Samsung Securities Co., Ltd for KRW 2,000,000,000, NH-Orion Mezzanine New Technology Fund No. 1 for KRW 1,500,000,000 and NH Fine Value No. 1 New Technology Fund for KRW 1,000,000,000 and others.The Bonds are 100% convertible into 1,391,207 common shares of the company at a conversion price value of KRW 10,782 and carry interest rate of 0% and maturity interest rate of 0%. The conversion billing period starts from May 28, 2027 to April 28, 2031. The transaction has been approved by the board of directors of the company. The Bonds have a maturity date of May 28, 2031. The transaction is expected to close on May 28, 2026.The transaction is subject to 1 year hold period.お知らせ • Mar 13KOREA PHARMA Co., Ltd., Annual General Meeting, Mar 27, 2026KOREA PHARMA Co., Ltd., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: seminar room, 317, seja-ro, gyeonggi-do, hwaseong South KoreaUpcoming Dividend • Dec 22Upcoming dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 28 April 2026. Trailing yield: 0.4%. Lower than top quartile of South Korean dividend payers (3.6%). Lower than average of industry peers (0.8%).Board Change • Nov 11Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Outside Director Euna Lee was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Nov 07KOREA PHARMA Co., Ltd. announces Annual dividend, payable on April 28, 2026KOREA PHARMA Co., Ltd. announced Annual dividend of KRW 50.0000 per share payable on April 28, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.New Risk • Nov 04New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩143.3b (US$99.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 21% per year over the past 5 years. High level of non-cash earnings (30% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (1.7% net profit margin). Market cap is less than US$100m (₩143.3b market cap, or US$99.6m).New Risk • Aug 28New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 30% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 21% per year over the past 5 years. High level of non-cash earnings (30% accrual ratio). Minor Risk Profit margins are more than 30% lower than last year (1.7% net profit margin).分析記事 • May 23KOREA PHARMA's (KOSDAQ:032300) Profits Appear To Have Quality IssuesKOREA PHARMA Co., Ltd.'s ( KOSDAQ:032300 ) robust recent earnings didn't do much to move the stock. We think this is...New Risk • Apr 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩147.1b (US$99.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 26% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩147.1b market cap, or US$99.3m).お知らせ • Mar 13KOREA PHARMA Co., Ltd., Annual General Meeting, Mar 28, 2025KOREA PHARMA Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:01 Tokyo Standard Time. Location: seminar room, 317, seja-ro, jeongnam-myeon, gyeonggi-do, hwaseong South KoreaUpcoming Dividend • Dec 20Upcoming dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 28 April 2025. Trailing yield: 0.3%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (1.1%).Valuation Update With 7 Day Price Move • Dec 16Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩15,960, the stock trades at a trailing P/E ratio of 58x. Average trailing P/E is 12x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 69% over the past three years.分析記事 • Nov 12Is KOREA PHARMA (KOSDAQ:032300) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Valuation Update With 7 Day Price Move • Nov 05Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩18,620, the stock trades at a trailing P/E ratio of 67.8x. Average trailing P/E is 15x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 66% over the past three years.分析記事 • Oct 16Optimistic Investors Push KOREA PHARMA Co., Ltd. (KOSDAQ:032300) Shares Up 29% But Growth Is LackingKOREA PHARMA Co., Ltd. ( KOSDAQ:032300 ) shareholders would be excited to see that the share price has had a great...Valuation Update With 7 Day Price Move • Oct 16Investor sentiment improves as stock rises 30%After last week's 30% share price gain to ₩20,950, the stock trades at a trailing P/E ratio of 76.3x. Average trailing P/E is 16x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 62% over the past three years.お知らせ • May 30Korea Pharma Co., Ltd Submits A New Drug Application to the Korean Ministry of Food and Drug Safety for the Review and Approval of Accrufer to Treat Patients with Iron Deficiency Anaemia in KoreaShield Therapeutics plc announced that its Accrufer partner for Korea, Korea Pharma Co., Ltd. (Korea Pharma) has submitted a New Drug Application (NDA) to the Korean Ministry of Food and Drug Safety (MFDS) for the review and approval of Accrufer to treat patients with iron deficiency anaemia in Korea. Pending a successful review, approval of Accrufer in Korea is anticipated in 2025. Korea Pharma's MFDS filing follows the successful completion of a pharmacokinetic (PK) study in Korea. The PK study confirms that the absorption of iron from Accrufer is comparable between patients in Korea and the patient population enrolled in the key clinical studies supporting Accrufer® effectiveness and safety.Reported Earnings • May 19First quarter 2024 earnings released: EPS: ₩121 (vs ₩7.00 in 1Q 2023)First quarter 2024 results: EPS: ₩121 (up from ₩7.00 in 1Q 2023). Revenue: ₩20.3b (flat on 1Q 2023). Net income: ₩1.32b (up ₩1.24b from 1Q 2023). Profit margin: 6.5% (up from 0.4% in 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 50 percentage points per year, which is a significant difference in performance.分析記事 • Mar 26KOREA PHARMA (KOSDAQ:032300) Seems To Use Debt Quite SensiblyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Upcoming Dividend • Dec 20Inaugural dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 27 December 2023. Payment date: 29 April 2024. This is the first dividend for KOREA PHARMA since going public. The average dividend yield among industry peers is 1.1%.New Risk • Dec 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.New Risk • Oct 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Upcoming Dividend • Dec 21Inaugural dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 28 April 2023. This is the first dividend for KOREA PHARMA since going public. The average dividend yield among industry peers is 1.0%.Reported Earnings • Nov 16Third quarter 2022 earnings released: EPS: ₩59.00 (vs ₩135 in 3Q 2021)Third quarter 2022 results: EPS: ₩59.00 (down from ₩135 in 3Q 2021). Revenue: ₩20.4b (up 6.0% from 3Q 2021). Net income: ₩648.4m (down 56% from 3Q 2021). Profit margin: 3.2% (down from 7.6% in 3Q 2021). The decrease in margin was driven by higher expenses.Reported Earnings • Nov 13Third quarter 2022 earnings released: EPS: ₩59.00 (vs ₩135 in 3Q 2021)Third quarter 2022 results: EPS: ₩59.00 (down from ₩135 in 3Q 2021). Revenue: ₩20.4b (up 6.0% from 3Q 2021). Net income: ₩648.4m (down 56% from 3Q 2021). Profit margin: 3.2% (down from 7.6% in 3Q 2021). The decrease in margin was driven by higher expenses.Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩26,100, the stock trades at a trailing P/E ratio of 65.1x. Average trailing P/E is 19x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 54% over the past year.Valuation Update With 7 Day Price Move • Jul 14Investor sentiment improved over the past weekAfter last week's 32% share price gain to ₩33,500, the stock trades at a trailing P/E ratio of 60.5x. Average trailing P/E is 22x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 39% over the past year.Valuation Update With 7 Day Price Move • Jun 29Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩23,850, the stock trades at a trailing P/E ratio of 43.1x. Average trailing P/E is 21x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 53% over the past year.Buying Opportunity • Jun 23Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 49%. The fair value is estimated to be ₩26,188, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last year. Earnings per share has grown by 63%.Valuation Update With 7 Day Price Move • Jun 14Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩25,900, the stock trades at a trailing P/E ratio of 46.8x. Average trailing P/E is 22x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 42% over the past year.Valuation Update With 7 Day Price Move • Jan 21Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩38,000, the stock trades at a forward P/E ratio of 70x. Average forward P/E is 19x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 46% over the past year.Upcoming Dividend • Dec 22Inaugural dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 28 April 2022. The company is not currently making a profit but it is cash flow positive. This is the first dividend for KOREA PHARMA since going public. The average dividend yield among industry peers is 0.8%.Is New 90 Day High Low • Jan 13New 90-day high: ₩31,950The company is up 1.0% from its price of ₩31,700 on 15 October 2020. The South Korean market is up 29% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 14% over the same period.分析記事 • Jan 08What You Need To Know About KOREA PHARMA Co., Ltd.'s (KOSDAQ:032300) Investor CompositionA look at the shareholders of KOREA PHARMA Co., Ltd. ( KOSDAQ:032300 ) can tell us which group is most powerful...Is New 90 Day High Low • Dec 09New 90-day low: ₩20,200The company is down 24% from its price of ₩26,750 on 10 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 6.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、KOREA PHARMA は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測KOSDAQ:A032300 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202691,417-2,473-13,9385,096N/A12/31/202587,601-2,640-17,0382,687N/A9/30/202590,112174-17,2924,722N/A6/30/202585,3381,448-18,8713,246N/A3/31/202581,7832,9902,0416,064N/A12/31/202481,2773,7924,2458,046N/A9/30/202479,7993,0003,8315,795N/A6/30/202480,4032,9953,3505,171N/A3/31/202483,1371,3273,4486,012N/A12/31/202383,240842,1434,819N/A9/30/202384,549-2,4302,7555,417N/A6/30/202385,160-3,0304,3137,333N/A3/31/202382,782-1,5923,2106,214N/A12/31/202281,029-1,1195,5278,279N/A9/30/202281,5093,5506,5249,857N/A6/30/202280,3534,3724,3228,078N/A3/31/202280,2836,0355,1748,460N/A12/31/202179,5776,3683,7427,192N/A9/30/202175,0895,4681,0554,613N/A6/30/202174,3944,949-2,427527N/A3/31/202172,8293,297-3,128-279N/A12/31/202071,5103,159-3,518-874N/A9/30/202069,8533,075-2,688-350N/A3/31/202066,4954,4262,4734,727N/A12/31/201966,1365,528N/A7,544N/A12/31/201860,4843,828N/A4,884N/A12/31/201756,0182,514N/A4,019N/A12/31/201653,702-149N/A1,287N/A12/31/201560,0584,341N/A569N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: A032300の予測収益成長が 貯蓄率 ( 3.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: A032300の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: A032300の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: A032300の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: A032300の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A032300の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/11 15:33終値2026/08/11 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋KOREA PHARMA Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Jongsun ParkEugene Investment & Securities Co Ltd.Taehee KimMirae Asset Securities Co., Ltd.
お知らせ • May 29KOREA PHARMA Co., Ltd. announced that it has received KRW 15 billion in fundingOn May 28, 2026, KOREA PHARMA Co., Ltd. closed the transaction.
お知らせ • May 22KOREA PHARMA Co., Ltd. announced that it expects to receive KRW 15 billion in fundingKOREA PHARMA Co., Ltd. has announced a private placement of Series 5 Unregistered Unsecured Private Convertible Bonds of the company to raise gross proceeds of KRW 15,000,000,000 on May 20, 2026. The transaction includes participation from The Time-M Private Equity Trust advised by Samsung Securities Co., Ltd for KRW 2,000,000,000, NH Absolute Return General Private Investment Trust No. 1 advised by Samsung Securities Co., Ltd for KRW 2,000,000,000, NH-Orion Mezzanine New Technology Fund No. 1 for KRW 1,500,000,000 and NH Fine Value No. 1 New Technology Fund for KRW 1,000,000,000 and others.The Bonds are 100% convertible into 1,391,207 common shares of the company at a conversion price value of KRW 10,782 and carry interest rate of 0% and maturity interest rate of 0%. The conversion billing period starts from May 28, 2027 to April 28, 2031. The transaction has been approved by the board of directors of the company. The Bonds have a maturity date of May 28, 2031. The transaction is expected to close on May 28, 2026.The transaction is subject to 1 year hold period.
お知らせ • Mar 13KOREA PHARMA Co., Ltd., Annual General Meeting, Mar 27, 2026KOREA PHARMA Co., Ltd., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: seminar room, 317, seja-ro, gyeonggi-do, hwaseong South Korea
Upcoming Dividend • Dec 22Upcoming dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 28 April 2026. Trailing yield: 0.4%. Lower than top quartile of South Korean dividend payers (3.6%). Lower than average of industry peers (0.8%).
Board Change • Nov 11Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Outside Director Euna Lee was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 07KOREA PHARMA Co., Ltd. announces Annual dividend, payable on April 28, 2026KOREA PHARMA Co., Ltd. announced Annual dividend of KRW 50.0000 per share payable on April 28, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.
New Risk • Nov 04New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩143.3b (US$99.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 21% per year over the past 5 years. High level of non-cash earnings (30% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (1.7% net profit margin). Market cap is less than US$100m (₩143.3b market cap, or US$99.6m).
New Risk • Aug 28New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 30% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 21% per year over the past 5 years. High level of non-cash earnings (30% accrual ratio). Minor Risk Profit margins are more than 30% lower than last year (1.7% net profit margin).
分析記事 • May 23KOREA PHARMA's (KOSDAQ:032300) Profits Appear To Have Quality IssuesKOREA PHARMA Co., Ltd.'s ( KOSDAQ:032300 ) robust recent earnings didn't do much to move the stock. We think this is...
New Risk • Apr 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩147.1b (US$99.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 26% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩147.1b market cap, or US$99.3m).
お知らせ • Mar 13KOREA PHARMA Co., Ltd., Annual General Meeting, Mar 28, 2025KOREA PHARMA Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:01 Tokyo Standard Time. Location: seminar room, 317, seja-ro, jeongnam-myeon, gyeonggi-do, hwaseong South Korea
Upcoming Dividend • Dec 20Upcoming dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 28 April 2025. Trailing yield: 0.3%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (1.1%).
Valuation Update With 7 Day Price Move • Dec 16Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩15,960, the stock trades at a trailing P/E ratio of 58x. Average trailing P/E is 12x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 69% over the past three years.
分析記事 • Nov 12Is KOREA PHARMA (KOSDAQ:032300) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Valuation Update With 7 Day Price Move • Nov 05Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩18,620, the stock trades at a trailing P/E ratio of 67.8x. Average trailing P/E is 15x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 66% over the past three years.
分析記事 • Oct 16Optimistic Investors Push KOREA PHARMA Co., Ltd. (KOSDAQ:032300) Shares Up 29% But Growth Is LackingKOREA PHARMA Co., Ltd. ( KOSDAQ:032300 ) shareholders would be excited to see that the share price has had a great...
Valuation Update With 7 Day Price Move • Oct 16Investor sentiment improves as stock rises 30%After last week's 30% share price gain to ₩20,950, the stock trades at a trailing P/E ratio of 76.3x. Average trailing P/E is 16x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 62% over the past three years.
お知らせ • May 30Korea Pharma Co., Ltd Submits A New Drug Application to the Korean Ministry of Food and Drug Safety for the Review and Approval of Accrufer to Treat Patients with Iron Deficiency Anaemia in KoreaShield Therapeutics plc announced that its Accrufer partner for Korea, Korea Pharma Co., Ltd. (Korea Pharma) has submitted a New Drug Application (NDA) to the Korean Ministry of Food and Drug Safety (MFDS) for the review and approval of Accrufer to treat patients with iron deficiency anaemia in Korea. Pending a successful review, approval of Accrufer in Korea is anticipated in 2025. Korea Pharma's MFDS filing follows the successful completion of a pharmacokinetic (PK) study in Korea. The PK study confirms that the absorption of iron from Accrufer is comparable between patients in Korea and the patient population enrolled in the key clinical studies supporting Accrufer® effectiveness and safety.
Reported Earnings • May 19First quarter 2024 earnings released: EPS: ₩121 (vs ₩7.00 in 1Q 2023)First quarter 2024 results: EPS: ₩121 (up from ₩7.00 in 1Q 2023). Revenue: ₩20.3b (flat on 1Q 2023). Net income: ₩1.32b (up ₩1.24b from 1Q 2023). Profit margin: 6.5% (up from 0.4% in 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 50 percentage points per year, which is a significant difference in performance.
分析記事 • Mar 26KOREA PHARMA (KOSDAQ:032300) Seems To Use Debt Quite SensiblyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Upcoming Dividend • Dec 20Inaugural dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 27 December 2023. Payment date: 29 April 2024. This is the first dividend for KOREA PHARMA since going public. The average dividend yield among industry peers is 1.1%.
New Risk • Dec 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
New Risk • Oct 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Upcoming Dividend • Dec 21Inaugural dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 28 April 2023. This is the first dividend for KOREA PHARMA since going public. The average dividend yield among industry peers is 1.0%.
Reported Earnings • Nov 16Third quarter 2022 earnings released: EPS: ₩59.00 (vs ₩135 in 3Q 2021)Third quarter 2022 results: EPS: ₩59.00 (down from ₩135 in 3Q 2021). Revenue: ₩20.4b (up 6.0% from 3Q 2021). Net income: ₩648.4m (down 56% from 3Q 2021). Profit margin: 3.2% (down from 7.6% in 3Q 2021). The decrease in margin was driven by higher expenses.
Reported Earnings • Nov 13Third quarter 2022 earnings released: EPS: ₩59.00 (vs ₩135 in 3Q 2021)Third quarter 2022 results: EPS: ₩59.00 (down from ₩135 in 3Q 2021). Revenue: ₩20.4b (up 6.0% from 3Q 2021). Net income: ₩648.4m (down 56% from 3Q 2021). Profit margin: 3.2% (down from 7.6% in 3Q 2021). The decrease in margin was driven by higher expenses.
Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩26,100, the stock trades at a trailing P/E ratio of 65.1x. Average trailing P/E is 19x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 54% over the past year.
Valuation Update With 7 Day Price Move • Jul 14Investor sentiment improved over the past weekAfter last week's 32% share price gain to ₩33,500, the stock trades at a trailing P/E ratio of 60.5x. Average trailing P/E is 22x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 39% over the past year.
Valuation Update With 7 Day Price Move • Jun 29Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩23,850, the stock trades at a trailing P/E ratio of 43.1x. Average trailing P/E is 21x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 53% over the past year.
Buying Opportunity • Jun 23Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 49%. The fair value is estimated to be ₩26,188, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last year. Earnings per share has grown by 63%.
Valuation Update With 7 Day Price Move • Jun 14Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩25,900, the stock trades at a trailing P/E ratio of 46.8x. Average trailing P/E is 22x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 42% over the past year.
Valuation Update With 7 Day Price Move • Jan 21Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩38,000, the stock trades at a forward P/E ratio of 70x. Average forward P/E is 19x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 46% over the past year.
Upcoming Dividend • Dec 22Inaugural dividend of ₩50.00 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 28 April 2022. The company is not currently making a profit but it is cash flow positive. This is the first dividend for KOREA PHARMA since going public. The average dividend yield among industry peers is 0.8%.
Is New 90 Day High Low • Jan 13New 90-day high: ₩31,950The company is up 1.0% from its price of ₩31,700 on 15 October 2020. The South Korean market is up 29% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 14% over the same period.
分析記事 • Jan 08What You Need To Know About KOREA PHARMA Co., Ltd.'s (KOSDAQ:032300) Investor CompositionA look at the shareholders of KOREA PHARMA Co., Ltd. ( KOSDAQ:032300 ) can tell us which group is most powerful...
Is New 90 Day High Low • Dec 09New 90-day low: ₩20,200The company is down 24% from its price of ₩26,750 on 10 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 6.0% over the same period.